Denosumab: Recent update in postmenopausal osteoporosis

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)
60 Downloads (Pure)


Postmenopausal osteoporosis is a major concern to public health. Fractures are the major clinical consequen-ce of osteoporosis and are associated with substantial mor bidity, mortality and health care costs. Bone strength determinants such as bone mineral density and bone quality parameters are determined by lifelong remodeling of skeletal tissue. Receptor activator of nuclear factor-kB ligand (RANKL) is a cytokine essential for osteoclast differentiation, activation and survival. Denosumab (Prolia®) is a fully human monoclonal antibody for RANKL, which selectively inhibits osteoclastogenesis, being recently approved for the treatment of postmenopausal osteoporosis in women at a high or increased risk of fracture by the FDA in the United Sates and by the European Medicines Agency in Europe since June 2010. FREEDOM, DECIDE and STAND are the phase 3 trials comparing denosumab with placebo and alendronate in postmenopausal osteoporosis. The authors aim to update denosumab role in postmenopausal osteoporosis with a physiopathological review.

Original languageEnglish
Pages (from-to)302-313
Number of pages12
JournalActa Reumatológica Portuguesa
Issue number4
Publication statusPublished - Oct 2012


  • Denosumab
  • Osteoprotegerin
  • Postmenopausal osteoporosis
  • Rank
  • Rankl


Dive into the research topics of 'Denosumab: Recent update in postmenopausal osteoporosis'. Together they form a unique fingerprint.

Cite this